CCIE World-class Pharmaceutical R & D Platform in Chengdu
 |
 |
 |
 |
 |
Besides further expansion of foreign trade, oversea project contracting, CCIE also intensify its efforts to actively expand the third company's business plate- investment.
On March 2, 2012, the lead compound screening platform with international advanced level, invested by CCIE was decided to be built in Chengdu High-tech Zone. The same day, the assistant of Chengdu Mayor and AC director of high-tech Zone Han Chunlin on behalf of the Chengdu Hi-tech Zone and the representative from investing party Dr. Li Jin, officially signed a settled agreement. Deputy AC director of Hi-tech Zone Mr. Fu Xuekun with relevant department principals, Mr. Lu Kai the president of CCIE, Mr. Xu Chenhui vice president of CCIE, and Project Manager Mr. Yang Chao from CCIE participated in the project signing ceremony.
After the signing ceremony, the Chengdu Municipal Committee and the secretary of Party Working Committee of the High-tech Zone Jing Gang met with the representatives from the investor. Mr.Jing spoke highly of CCIE for actively investing in high-tech field to enhance the pharmaceutical R & D level in Chengdu, expressed the appreciation for the decision of Dr. Li Jing returning home to make contribution after a successful career, and also indicated High-tech Zone will provide preferential policies and create a favorable condition for the smooth development of the project
The total investment of the project is 100 million RMB，designed to build a DNA encoding compounds library with 50 million to 100 million compound and a highly efficient molecular screening platform within next 2 years. It is expected to achieve 120 million sales incomes from the third years of the project construction. Due to the novelty of the technology path which is a international leading technology and also exclusive in the domestic, so the platform is expected to be a world-class R & D platform for the innovation of the new drug and will greatly enhance the Pharmaceutical R & D level of Chengdu and make Chengdu integrated into the industrial chain of global drug development.
Dr. Li Jin, the partner of CCIE had worked at Fortune 500 companies, one of the leading global pharmaceutical companies, AstraZeneca, UK. With many years experiences engaged in the related research in the field, Dr. Li Jin broke the traditional method that applying high-throughput cluster device to screen the active compounds and then obtaining the lead compounds from the active compounds. Dr. Li will utilize the world's leading technology “DNA encoding compounds "which will greatly reduce the construction time for the library and cost of the compound, while also significantly reduce the compounds screening time (from several months to few weeks).
